BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nezutatug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nezutatug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05910827-2517@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nezutatug: Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Nezutatug\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cetuximab +/- 
 Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nez
 utatug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05910827
URL:https://assetmemo.bio/drug/nezutatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919537-2517@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Nezutatug: Phase 1 readout est. (NCT05919537)
DESCRIPTION:Nezutatug\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  of an Anti-HER3 Antibody\, HMBD-001\, With or Without Chemotherapy in Pat
 ients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation\nEstimat
 ed primary completion: 1 March 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nezutatug#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05919537
URL:https://assetmemo.bio/drug/nezutatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
